Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-96191 in Relapsed or Refractory Acute Myeloid Leukemia
NCT04789655Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jun 2021
- Primary completion
- Apr 2025
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of CC-96191 in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Primary endpoints: Dose limiting toxicities, Maximum tolerated dose and 1 more. Started Jun 2021; status: terminated.
02
Drugs
CC-96191
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04789655.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04789655.